AbbVie stock rallies with price holding above key moving averages: weekly outlook

Traders Union
All News
Financial News
AbbVie gains 7.22% this week

Highlights

AbbVie price action remains bullish with the stock trading near the top of its weekly range following a 7.22% gain.
Technical indicators show mixed momentum, with oscillators signaling overbought conditions and high weekly volatility of 7.84%.
The 7-day outlook forecasts consolidation between $229.68 and $233.55, with equal probability for a breakout or near-term pullback.

Acquisition and regulatory wins drive optimism after exclusivity loss

AbbVie revealed the acquisition of Apogee Therapeutics in a $10.9 billion cash deal, adding clinical-stage immunology assets such as zumilokibart to its portfolio. This move aims to strengthen the company’s immunology segment after Humira’s exclusivity period ended and builds on an already robust pipeline. Additionally, the European Commission approved Skyrizi for use in children and adolescents with moderate to severe plaque psoriasis, further supporting the company’s product expansion in Europe.

Overbought momentum and mixed signals after holding above supports this week

On the weekly chart, ABBV holds a decisive position above all key W1 moving averages, with MA-20, MA-50, and MA-200 providing immediate and substantial dynamic support. Weekly resistance is located near $233.55, while support is observed at $229.68, aligning with MA-50 and the lower end of the week’s anticipated range. Weekly RSI and Commodity Channel Index readings reflect active buying momentum, yet the Stochastic RSI and Bull/Bear Power signal strong overbought conditions. The MACD and ADX remain neutral, indicating a lack of clear directional conviction, while the Awesome Oscillator supports the overall bullish setup. Volatility this week was notably high at 7.84%.

Sideways outlook expected as overbought rally meets neutral momentum

For the next 7 trading days, ABBV is likely to consolidate sideways just below recent highs, with a projected trading range of $229.68 to $233.55. Signals are split — the probability of breaking higher or moving lower stands at roughly 50% each, based on neutral momentum indicators offsetting the current overbought readings. A bullish scenario would see ABBV breaking above $233.55 and continuing its rally toward new highs, while a bearish scenario involves a pullback below $229.68 and possible short-term correction from overbought conditions. The baseline expectation is for ABBV to remain rangebound, barring any further significant news.

Jainam Mehta, market strategist, notes AbbVie’s robust 7.22% rally this week as the stock firmly outperformed key moving averages. He points to the Apogee Therapeutics acquisition and positive regulatory news as reinforcing the bullish narrative, yet cautions on overbought readings and elevated volatility. The analyst views a 50/50 split in breakout versus pullback scenarios, favoring tactical range-trading strategies between $229.68 and $233.55 for the coming week. "With technical momentum stretched but structural support strong, I expect sideways consolidation — and see contrarian entries favored only if the price breaks decisively out of this range."

Earlier, analysts noted that AbbVie’s acquisition of Apogee Therapeutics signaled a strategic push to strengthen its immunology portfolio and sustain long-term growth. With the stock extending its breakout and overbought conditions intensifying, traders should closely monitor the $233.55 resistance level for evidence of renewed momentum or an impending reversal in the coming sessions.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.